Executive Summary

Download Executive Summary

Who We Are

Oncore Pharma is a liquid biopsy diagnostics company which distributes ColonSentry® through a global licensing and co-marketing agreement.

To date, more than 100,000 U.S. patients have benefited from the ColonSentry® test. It’s time for the rest of the world to have access to an early detection of Colorectal Cancer

OUR MISSION: Oncore Pharma is a catalyst for research, development and commercialization of innovative products for the diagnosis, care and cure of early stage cancer patients

OUR VISION: Every individual should have the opportunity to receive the earliest diagnosis possible and the most appropriate / least invasive treatment there is.

Our 1st Product (under global license)

ColonSentry® is an advanced blood-based molecular diagnostic assay that measures the expression of seven genetic biomarkers for the early detection of colorectal cancer, using a patented technology called The Sentinel Principle®.

This 7-gene blood-based biomarker panel can stratify subjects according to their current relative risk across a broad range in an average-risk population.

Validated in a study of 10,000 patients in North America.

Prescribed to over 100,000 patients in the U.S.

Our Strategy

The American Cancer Society recommends that people at average risk of colorectal cancer start regular screening at age 45. There are 590,8M men and 674,9M women for a total 1,27 billion people between 45 to 80 years old outside the USA!

To effectively reach that target audience:

We will use a network of already established liquid biopsy distributors in 26 countries covering 2 continents where ColonSentry® would be an “add on” to their existing detection tests in other disease areas such as breast, prostate and lung cancer.

We will offer this early detection test to Insurance companies.

We will distribute directly to privately owned clinics in Canada.

Advantages

Find cancers in their earliest stages, when patient survival is highest and costs are dramatically reduced.

The test does not require fasting, dietary restrictions or special instructions.

Does not require patients to handle or provide any stool samples.

The procedure is simple, convenient, and blood can be drawn at an exam before patients leave the office.

The prescribing physician receives the results in a pdf format 5 to 7 days later.

Multiple Factors Driving Adoption

  • Blood Test has a higher compliance rate of (95 to 98%) vs 67% for standard stool test
  • High Success Rate in Finding Cancer at Stage I and II with a 99.6% negative predictive value
  • Survival rate at 5 years is 91% when found early and cost of treatment is dramatically lowered.
  • Simple, visual and easy to understand results sent within 5 days in a pdf format to the treating physician to asses the need for colonoscopy or biopsy

Pipeline

Using that same patented, robust and proven Sentinel Principle® Technology Platform, we are helping validate Aristotle. It’s a panel for simultaneously screening all 10 Cervical, Endometrial, Breast, Ovarian, Liver, Bladder, Nasopharyngeal, Colorectal, Stomach and Prostate Cancer from a SINGLE blood sample.

To acquire our own IP, we will add leukemia as an 11th cancer detected and will also expand this early detection platform for neurodegenerative disorders and metabolic syndromes by collaborating with local universities’ research team.

ColonSentry® Harnessing the Power of Gene Expression for Early Colorectal Cancer Detection